Potentiation of brain stimulation reward by morphine: Effects of neurokinin-1 receptor antagonism

Department of Neurology and Bowles Center for Alcohol Studies, University of North Carolina at Chapel Hill, 170 Manning Dr., CB 7025, Chapel Hill, NC 27599-7025, USA.
Psychopharmacology (Impact Factor: 3.88). 09/2011; 220(1):215-24. DOI: 10.1007/s00213-011-2469-z
Source: PubMed


The abuse potential of opioids may be due to their reinforcing and rewarding effects, which may be attenuated by neurokinin-1 receptor (NK1R) antagonists.
This study was conducted to measure the effects of opioid and NK1R blockade on the potentiation of brain stimulation reward (BSR) by morphine using the intracranial self-stimulation method.
Adult male C57BL/6J mice (n = 15) were implanted with unipolar stimulating electrodes in the lateral hypothalamus and trained to respond for varying frequencies of rewarding electrical stimulation. The BSR threshold (θ(0)) and maximum response rate (MAX) were determined before and after intraperitoneal administration of saline, morphine (1.0-17.0 mg/kg), or the NK1R antagonists L-733,060 (1.0-17.0 mg/kg) and L-703,606 (1.0-17.0 mg/kg). In morphine antagonism experiments, naltrexone (0.1-1.0 mg/kg) or 10.0 mg/kg L-733,060 or L-703,606 was administered 15 min before morphine (1.0-10.0 mg/kg) or saline.
Morphine dose-dependently decreased θ(0) (maximum effect = 62% of baseline) and altered MAX when compared to saline. L-703,606 and L-733,060 altered θ(0); 10.0 mg/kg L-733,060 and L-703,606, which did not affect θ(0) or MAX, attenuated the effects of 3.0 and 10.0 mg/kg morphine, and 1.0 and 0.3 mg/kg naltrexone blocked the effects of 10.0 mg/kg morphine. Naltrexone given before saline did not affect θ(0) or MAX.
The decrease in θ(0) by morphine reflects its rewarding effects, which were attenuated by NK1R and opioid receptor blockade. These results demonstrate the importance of substance P signaling during limbic reward system activation by opioids.

Download full-text


Available from: C.J. Malanga, Oct 02, 2015
32 Reads
  • Source
    • "Adult (>P60) male mice (h/mOPRM1-118AA: n = 49; 118GG: n = 48) were implanted with stimulating electrodes in the medial forebrain bundle at the level of the lateral hypothalamus (coordinates: AP -1.3, ML -1.0, DV -5.0 mm) and were conditioned to perform intracranial self-stimulation as previously described (Robinson et al, 2012). During each testing session, mice responded during three consecutive series of 15 descending frequencies. "
  • Source
    • "Intracranial self-stimulation (ICSS) is an operant behavioral method in which mice respond for rewarding electrical stimulation of the medial forebrain bundle at the level of the lateral hypothalamus . All ICSS methods were done as previously described (Robinson et al., 2012), using the curve-shift method of ICSS (Carlezon and Chartoff, 2007). The maximum response rate (MAX) and the lowest frequency that sustained responding brain stimulation reward (BSR threshold, u 0 ) were compared before and after drug administration. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The hypothesis that functionally selective GPCR agonists may have enhanced therapeutic benefits has revitalized interest for many GPCR targets. In particular, although κ-opioid receptor (KOR) agonists are analgesic with a low risk of dependence and abuse, their utility is limited by a propensity to induce sedation, motor incoordination, hallucinations and dysphoria-like states. Several labs have produced a body of work implying that G-protein biased KOR agonists might be analgesic with fewer side-effects. Although this has been an intriguing hypothesis, suitably KOR selective and G-protein biased agonists have not been available to test this idea. Here we provide data using a G-protein biased agonist RB-64 which suggests that KOR-mediated G protein signaling induces analgesia and aversion, whereas β-arrestin 2 signaling may be associated with motor incoordination. Additionally, unlike unbiased KOR agonists, the G protein-biased ligand RB 64 does not induce sedation and does not have anhedonia-like actions, suggesting that a mechanism other than G protein signaling mediates these effects. Our findings provide the first evidence with a highly selective and G-protein biased tool compound that many, but not all, of the negative side effects of KOR agonists can be minimized by creating G protein biased KOR agonists.
    Journal of Pharmacology and Experimental Therapeutics 10/2014; 352(1). DOI:10.1124/jpet.114.216820 · 3.97 Impact Factor
  • Source
    • "The reductions in ICSS thresholds produced by morphine were associated with significant increases in the maximal rate of responding. These data are also consistent with previous reports (Altarifi and Negus 2011; Katsidoni et al. 2013; Robinson et al. 2012). Furthermore, both the curcuminoid mixture and curcumin I counteracted the increases in maximal rates of responding produced by morphine administration. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Rationale Recent animal studies reported that curcumin, the active constituent of Curcuma longa, has several central actions and may attenuate morphine tolerance. Objectives In the present study, we utilized the intracranial self-stimulation (ICSS) paradigm to examine the effects of the commercially available curcuminoid mixture and each one of its components, individually, on brain stimulation reward and on the reward-facilitating effect of morphine. Methods Male Sprague-Dawley rats were implanted with an electrode into the medial forebrain bundle and trained to respond for electrical stimulation using a rate-frequency paradigm. In the first study, rats were injected with graded doses either of the curcuminoid mixture, or curcumin I, or II, or III. In the second study, we examined whether a low dose of the curcuminoid mixture or each individual curcumin analogue composing it could counteract the reward-facilitating effect of morphine. Results At low doses, both the curcuminoid mixture and curcumin I did not affect brain stimulation reward, whereas, higher doses increased ICSS thresholds. Curcumin II and curcumin III did not affect brain stimulation reward at any doses. Subthreshold doses of the curcuminoid mixture and curcumin I inhibited the reward-facilitating effect of morphine. Conclusion Both the curcuminoid mixture and curcumin I lack hedonic properties and moderate the reward-facilitating effect of morphine. Our data suggest that curcumin interferes with brain reward mechanisms responsible for the expression of the acute reinforcing properties of opioids and provide evidence that curcumin may be a promising adjuvant for attenuating morphine's rewarding effects in patients who are under long-term opioid therapy.
    Psychopharmacology 05/2014; 231(23). DOI:10.1007/s00213-014-3603-5 · 3.88 Impact Factor
Show more